NAS:NEOG (USA) Also trade in: Germany

Neogen Corp

$ 58.61 0 (0%)
On watch
Volume: 118,593 Avg Vol (1m): 201,020
Market Cap $: 3.05 Bil Enterprise Value $: 2.81 Bil
P/E (TTM): 49.66 P/B: 4.97
Earnings Power Value 15.43
Net Current Asset Value 7.05
Tangible Book 8.51
Projected FCF 17.82
Median P/S Value 47.91
Graham Number 15.03
Peter Lynch Value 12.51
DCF (FCF Based) 21.31
DCF (Earnings Based) 22.61
1Y (-%)

Financial Strength : 10/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
96.93% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
NEOG: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.15, Med: 10000, Max: 10000
Current: 10000
0.15
10000
Equity-to-Asset 0.92
Equity-to-Asset ranked higher than
90.79% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
NEOG: 0.92
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.72, Med: 0.88, Max: 0.93
Current: 0.92
0.72
0.93
Interest Coverage No Debt
Interest Coverage ranked higher than
96.93% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 15605.52, Med: 76.01, Min: 0.54
NEOG: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 37.50
DISTRESS
GREY
SAFE
Beneish M-Score -2.39
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 16.33%
WACC 8.58%

Profitability & Growth : 8/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 16.61
Operating Margin ranked higher than
86.78% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
NEOG: 16.61
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: 16.61, Med: 18.15, Max: 20.75
Current: 16.61
16.61
20.75
Net Margin % 14.85
Net Margin ranked higher than
87.14% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
NEOG: 14.85
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: 11.38, Med: 12.17, Max: 15.7
Current: 14.85
11.38
15.7
ROE % 10.65
ROE ranked higher than
74.38% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
NEOG: 10.65
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: 9.68, Med: 11.23, Max: 13.38
Current: 10.65
9.68
13.38
ROA % 9.71
ROA ranked higher than
85.11% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
NEOG: 9.71
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: 8.68, Med: 9.79, Max: 11.42
Current: 9.71
8.68
11.42
ROC (Joel Greenblatt) % 33.78
ROC (Joel Greenblatt) ranked higher than
79.54% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
NEOG: 33.78
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: 33.35, Med: 39.04, Max: 52.57
Current: 33.78
33.35
52.57
3-Year Total Revenue Growth Rate 12.40
3-Year Revenue Growth Rate ranked higher than
67.03% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
NEOG: 10.8
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -15.3, Med: 13.4, Max: 26.4
Current: 10.8
-15.3
26.4
3-Year Total EBITDA Growth Rate 11.00
3-Year EBITDA Growth Rate ranked higher than
58.43% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
NEOG: 9.4
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: 15.5, Max: 40.1
Current: 9.4
0
40.1
3-Year EPS w/o NRI Growth Rate 21.50
3-Year EPS w/o NRI Growth Rate ranked higher than
57.67% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
NEOG: 21.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 15.1, Max: 31.9
Current: 21.5
0
31.9

» NEOG's 30-Y Financials

Financials (Next Earnings Date: 2019-07-18)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:NEOG

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 325412    SIC : 2835
Compare NAS:QDEL NAS:GHDX SHSE:603658 NAS:MYGN SZSE:300676 BSP:DASA3 NAS:MEDP NAS:NEO SHSE:603882 NAS:BEAT NYSE:NVTA SZSE:300463 SZSE:300244 SZSE:300482 BSP:FLRY3 TSE:4544 SZSE:300406 OSTO:SECT B NAS:SYNH NAS:VREX
Traded in other countries NG2.Germany
Address 620 Lesher Place, Lansing, MI, USA, 48912
Neogen Corp develops and markets a range of products related to food and animal safety. Its food safety segment sells diagnostic test kits to food producers and processors that detect harmful substances in human food and animal feed, like foodborne pathogens, natural toxins, food allergens, and pesticide residues. Most of these tests are disposable products. The animal safety segment manufactures pharmaceuticals, vaccines, veterinary instruments, rodenticides, and insecticides for the animal safety market. These products are largely used by the veterinary and agricultural industries. The animal safety segment generates over half of Neogen's revenue. The firm's customers are primarily located in the United States.

Ratios

Current vs industry vs history
PE Ratio (TTM) 49.66
PE Ratio ranked lower than
78.76% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35, Min: 0.33
NEOG: 49.66
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 21, Med: 49.16, Max: 75.98
Current: 49.66
21
75.98
Forward PE Ratio 48.78
Forward P/E ranked lower than
92.50% of 40 companies
in the Diagnostics & Research industry.
Industry Max: 78.74, Med: 9999, Min: 11.64
NEOG: 48.78
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 49.66
PE without NRI ranked lower than
78.76% of 113 companies
in the Diagnostics & Research industry.
Industry Max: 1345, Med: 35.56, Min: 0.34
NEOG: 49.66
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 21, Med: 49.16, Max: 75.98
Current: 49.66
21
75.98
Price-to-Owner-Earnings 60.79
Price-to-Owner-Earnings ranked lower than
77.63% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 1523.53, Med: 36.75, Min: 4.91
NEOG: 60.79
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 22.88, Med: 64.69, Max: 131.04
Current: 60.79
22.88
131.04
PB Ratio 4.97
PB Ratio ranked lower than
65.31% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
NEOG: 4.97
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.24, Med: 4.93, Max: 8.63
Current: 4.97
2.24
8.63
PS Ratio 7.38
PS Ratio ranked lower than
68.70% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
NEOG: 7.38
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 2.49, Med: 6.05, Max: 12.4
Current: 7.38
2.49
12.4
Price-to-Free-Cash-Flow 62.97
Price-to-Free-Cash-Flow ranked lower than
82.50% of 80 companies
in the Diagnostics & Research industry.
Industry Max: 1356.19, Med: 29.22, Min: 0.35
NEOG: 62.97
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 21.27, Med: 66.38, Max: 428.7
Current: 62.97
21.27
428.7
Price-to-Operating-Cash-Flow 47.04
Price-to-Operating-Cash-Flow ranked lower than
84.54% of 97 companies
in the Diagnostics & Research industry.
Industry Max: 1739.7, Med: 19.94, Min: 0.35
NEOG: 47.04
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 18.51, Med: 46.04, Max: 76.04
Current: 47.04
18.51
76.04
EV-to-EBIT 40.55
EV-to-EBIT ranked lower than
88.98% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
NEOG: 40.55
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: 13.8, Med: 30.9, Max: 69.3
Current: 40.55
13.8
69.3
EV-to-EBITDA 32.43
EV-to-EBITDA ranked lower than
87.12% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
NEOG: 32.43
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: 11.5, Med: 25.8, Max: 55.6
Current: 32.43
11.5
55.6
EV-to-Revenue 6.74
EV-to-Revenue ranked lower than
72.31% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
NEOG: 6.74
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 2.4, Med: 5.7, Max: 11.9
Current: 6.74
2.4
11.9
PEG Ratio 4.30
PEG Ratio ranked lower than
66.67% of 48 companies
in the Diagnostics & Research industry.
Industry Max: 128.13, Med: 3.26, Min: 0.32
NEOG: 4.3
Ranked among companies with meaningful PEG Ratio only.
PEG Ratio range over the past 10 years
Min: 1, Med: 3.74, Max: 6.58
Current: 4.3
1
6.58
Shiller PE Ratio 80.29
Shiller PE Ratio ranked lower than
82.05% of 39 companies
in the Diagnostics & Research industry.
Industry Max: 459.08, Med: 52.49, Min: 10.19
NEOG: 80.29
Ranked among companies with meaningful Shiller PE Ratio only.
Shiller PE Ratio range over the past 10 years
Min: 37.06, Med: 79.79, Max: 139.86
Current: 80.29
37.06
139.86
Current Ratio 12.33
Current Ratio ranked higher than
88.40% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
NEOG: 12.33
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 3.16, Med: 6.73, Max: 14.54
Current: 12.33
3.16
14.54
Quick Ratio 9.86
Quick Ratio ranked higher than
86.80% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
NEOG: 9.86
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.55, Med: 4.59, Max: 10.77
Current: 9.86
1.55
10.77
Days Inventory 129.84
Days Inventory ranked lower than
72.55% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
NEOG: 129.84
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 125.82, Med: 132.89, Max: 182.11
Current: 129.84
125.82
182.11
Days Sales Outstanding 70.06
Days Sales Outstanding ranked lower than
54.90% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
NEOG: 70.06
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 60.52, Med: 71.51, Max: 76.86
Current: 70.06
60.52
76.86
Days Payable 31.02
Days Payable ranked lower than
80.21% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
NEOG: 31.02
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 24.07, Med: 35.29, Max: 42.87
Current: 31.02
24.07
42.87

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.50
3-Year Share Buyback Rate ranked higher than
76.67% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
NEOG: -1.5
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -21.4, Med: -2.4, Max: 2.1
Current: -1.5
-21.4
2.1

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 6.89
Price-to-Tangible-Book ranked lower than
63.29% of 207 companies
in the Diagnostics & Research industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
NEOG: 6.89
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.49, Med: 4.97, Max: 11.86
Current: 6.89
1.49
11.86
Price-to-Projected-FCF 3.29
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
65.33% of 75 companies
in the Diagnostics & Research industry.
Industry Max: 449, Med: 2.41, Min: 0.47
NEOG: 3.29
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.96, Med: 2.62, Max: 10.75
Current: 3.29
0.96
10.75
Price-to-DCF (Earnings Based) 2.59
Price-to-Intrinsic-Value-DCF (Earnings Based) ranked lower than
64.71% of 17 companies
in the Diagnostics & Research industry.
Industry Max: 6.59, Med: 1.86, Min: 0.72
NEOG: 2.59
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
Price-to-Intrinsic-Value-DCF (Earnings Based) range over the past 10 years
Min: 1.23, Med: 2.15, Max: 3.89
Current: 2.59
1.23
3.89
Price-to-Median-PS-Value 1.22
Price-to-Median-PS-Value ranked lower than
70.98% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
NEOG: 1.22
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.14, Med: 0.5, Max: 1.99
Current: 1.22
0.14
1.99
Price-to-Peter-Lynch-Fair-Value 4.69
Price-to-Peter-Lynch-Fair-Value ranked lower than
90.00% of 30 companies
in the Diagnostics & Research industry.
Industry Max: 15.31, Med: 2.01, Min: 0.83
NEOG: 4.69
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 0.33, Med: 1.99, Max: 6.37
Current: 4.69
0.33
6.37
Price-to-Graham-Number 3.90
Price-to-Graham-Number ranked lower than
71.05% of 76 companies
in the Diagnostics & Research industry.
Industry Max: 49.42, Med: 3.98, Min: 0.39
NEOG: 3.9
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 0.89, Med: 2.88, Max: 6.23
Current: 3.9
0.89
6.23
Earnings Yield (Joel Greenblatt) % 2.46
Earnings Yield (Greenblatt) ranked higher than
60.38% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
NEOG: 2.46
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: 1.4, Med: 3.2, Max: 7.3
Current: 2.46
1.4
7.3
Forward Rate of Return (Yacktman) % 11.76
Forward Rate of Return ranked higher than
62.86% of 70 companies
in the Diagnostics & Research industry.
Industry Max: 7802.99, Med: 8.45, Min: -35.9
NEOG: 11.76
Ranked among companies with meaningful Forward Rate of Return only.
Forward Rate of Return range over the past 10 years
Min: 11.7, Med: 15.8, Max: 21.9
Current: 11.76
11.7
21.9

More Statistics

Revenue (TTM) (Mil) $ 416.87
EPS (TTM) $ 1.18
Beta 1.03
Volatility % 39.81
52-Week Range $ 50.6 - 97.38
Shares Outstanding (Mil) 52.12

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N